Stay tuned and follow the latest developments and news in Molecular Oncology.
The recent results of the Trial Assigning IndividuaLized Options for Treatment – RX (TAILORx) study, the largest clinical trial for breast cancer ever made with more than 10.000 patients has finally shown that more than 70% of women with early-stage breast cancer do not benefit from chemotherapy.
Breast cancer is known to be the most common cancer type in women nowadays with more than 1.600.000 incidents per year in a global basis.
Even though breast cancer rates among women are higher than ever, good news is that it has a good prognosis if diagnosed at an early stage. The mortality rates have been decreased significantly, though, and the main reason for this is the new era in molecular oncology that introduces us in the molecular profiling of each cancer patient in order to personalize his treatment according to his unique molecular characteristics.
The Oncotype DX® Breast Recurrence Score is the only assay approved by all the major internationally accepted clinical practice guidelines and it’s the only prognostic and predictive assay for patients with early-stage breast cancer positive estrogen receptors (ER) and HER-2 negative. The Oncotype DX® Breast Recurrence Score identifies the likelihood of chemotherapy benefit for each patient and also quantifies the risk of distant recurrence for each breast cancer patient.
This is extremely important since the physicians are now able to categorize the patients in subgroups according to their clinical characteristics and their Recurrence Score® result and construct the most suitable treatment plan for each of them. We can now definitely speak for a new era of personalized cancer treatment, leaving behind all the “One-for-All” treatment plans that were proved to be an inaccurate option for many cases.
The Oncotype DX® Breast Recurrence Score is performed in Redwood, US. By Genomic Health, Inc. and it’s being exclusively distributed in our local market by Genekor Medical S.A.